Small-batch brewers are starting to tinker with biologic drugs to meet their own medical needs. A side effect of their success would be a disruption to how big pharma makes and distributes drugs.
Negotiators from 11 countries have been racing to resurrect the near-dead Trans-Pacific Partnership Agreement before the Asia-Pacific Economic Cooperation (APEC) summit this weekend.
Rather than being designed by chemists, this class of pharmaceuticals is produced by living cells. Here's where they come from and how they work.
What can Australia expect from the Trans-Pacific Partnership? We asked experts about to nominate some winners and losers.
Before the last round of negotiations, only a handful of issues remained in the way of concluding the TPP. A potential deal-breaker for Australia was intellectual property protections for biologics.
Over the next few weeks, the trade minister will be under intense pressure to renege on the government’s commitment to reject anything in the Trans Pacific Partnership that could undermine the PBS.
Biologics are widely accepted as the most effective way of treating certain diseases. They have become the fastest-growing class of therapeutic compounds, with about 300 now available for human use.
Hope, fear, and desperation, along with the unique characteristics of the cancer drug market, create a “perfect storm” that continues to drive up prices for cancer drugs.